MAIA Director Stan Smith Receives Option Grant for 38.8K Shares
MAIA Biotechnology, Inc.
Subscribe to track MAIA
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
MAIA Director Stan Smith Receives Option Grant for 38.8K Shares
Company: MAIA Biotechnology, Inc. (MAIA)
Form: 4 | Filed: 2026-10-02
Significance: Low
Insider: Stan Smith Relationship: Director
Transaction: • Type: Grant (Stock Options) • Shares: 38,871 • Exercise Price: $1.18 • Grant Price: $0.00 • Owned After: 38,871 derivative options • Nature: Indirect (The Stan V. Smith Trust Dated 1993)
Key Insight: Routine director equity compensation under the company's 2021 Equity Incentive Plan with immediate vesting. Totaling 0.06% of outstanding shares, dilution impact is negligible.
Comprehensive Analysis
SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Director Stan Smith received a routine annual option award for 38,871 shares exercisable at $1.18.
- Market Impact: Neutral; standard director equity compensation with negligible dilution.
Company Information
| Field | Value |
|---|---|
| Company | MAIA Biotechnology, Inc. |
| Ticker Symbol | MAIA |
| CIK | 0001878313 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Stan Smith |
| CIK | 0001913199 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2026-09-30 |
| Transaction Code | A (Award/Grant) |
| Security Type | Stock Options |
| Shares Involved | 38,871 |
| Price Per Share | $0.00 (Exercise Price: $1.18) |
| Total Value | $0.00 |
| Shares Owned After | 38,871 |
| Ownership Type | Indirect (The Stan V. Smith Trust Dated 1993) |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $0.00 (Notional: $45,868) |
| % of Market Cap | <0.01% |
| Shares Transacted | 38,871 |
| % of Shares Outstanding | 0.06% |
| Post-Transaction Ownership | 38,871 options (0.06% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: At a $70M market capitalization, this $45.9K notional award represents less than 0.07% of company equity value.
- Ownership Concentration: Modest indirect derivative holding via family trust.
- Dilution Impact: Minimal dilution potential of 0.06% relative to 60.8M common shares outstanding.
- Transaction Significance: Routine compensation grant with negligible market implications.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Non-open-market routine board compensation.
Volume & Sentiment
- Expected Volume Impact: None expected.
- Sentiment Indicator: Neutral
Additional Context
Transaction Notes
- Timing: Effective September 30, 2026, coinciding with the end of Q3.
- Special Circumstances: Granted under the MAIA Biotechnology 2021 Equity Incentive Plan; fully vested upon grant date with a 10-year expiration term (September 30, 2036).
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.